Tenofovir for the treatment of hepatitis B virus

Pharmacotherapy

Volumn 29, Issue 10, 2009, Pages 1212-1227

  Jenh, Alice M ^a   Thio, Chloe L ^b   Pham, Paul A ^b  

^a JOHNS HOPKINS HOSPITAL   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chronic hepatitis B virus; HBV; Nucleotide analog reverse transcriptase inhibitor; Tenofovir disoproxil fumarate

Indexed keywords

ACICLOVIR; ADEFOVIR; ADEFOVIR DIPIVOXIL; ALPHA2A INTERFERON; ALPHA2B INTERFERON; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; CIDOFOVIR; DIDANOSINE; EMTRICITABINE; ENTECAVIR; GANCICLOVIR; LAMIVUDINE; PEGINTERFERON ALPHA2A; PLACEBO; PROBENECID; RITONAVIR; STAVUDINE; TELBIVUDINE; TENOFOVIR; TENOFOVIR DISOPROXIL; TRIMETHOPRIM; VALACICLOVIR; VALGANCICLOVIR;

ABDOMINAL PAIN; ACUTE KIDNEY TUBULE NECROSIS; ANTIVIRAL RESISTANCE; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; BACKACHE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CROSS RESISTANCE; DECOMPENSATED LIVER CIRRHOSIS; DEPRESSION; DIARRHEA; DIZZINESS; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; FANCONI RENOTUBULAR SYNDROME; FATIGUE; FATTY LIVER; HEADACHE; HEPATITIS B; HEPATITIS B VIRUS; HEPATOMEGALY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERSTITIAL NEPHRITIS; KIDNEY TUBULE DISORDER; LACTIC ACIDOSIS; LIVER CELL; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; NAUSEA; NEPHROGENIC DIABETES INSIPIDUS; NEPHROTOXICITY; PAIN; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; THROMBOCYTOPENIA; VIRUS REPLICATION;

ADENINE; ANTIVIRAL AGENTS; DRUG APPROVAL; DRUG INTERACTIONS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; PHOSPHONIC ACIDS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 70349658098     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.29.10.1212     Document Type: Article

References (70)

1. Center for Disease Control and Prevention, Division of Viral Hepatitis. Hepatitis B FAQs for health professionals, July 2008. Available from http://www.cdc.gov/hepatitis/HBV/HBVfaq.htm#overview. Accessed September 1, 2008.
2. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007;45:507-539
3. Ayoub WS, Keeffe EB. Review article: current antiviral therapy of chronic hepatitis B. Aliment Pharmacol Ther 2008;28:167-177 (Pubitemid 351861968)
4. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295:65-73. (Pubitemid 43042691)
5. Gilead Sciences, Inc. Viread (tenofovir disoproxil fumarate) package insert. Foster City, CA; 2008.
6. Keeffe EB, Dieterich DT, Han SH, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol 2008;6:1315-1341
7. Leung N. Recent data on treatment of chronic hepatitis B with nucleos(t)ide analogues. Hepatol Int 2008;2:163-178 (Pubitemid 351650144)
8. Lok AS, Lai CL, Leung N, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003;125:1714-1722 (Pubitemid 37500436)
9. Chang TT, Lai CL, Chien RN, et al. Four years of lamivudine treatment in Chinese patients with chronic hepatitis B. J Gastroenterol Hepatol 2004;19:1276-1282 (Pubitemid 39481762)
10. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006;131:1743-1751 (Pubitemid 44958517)
11. Liaw YF, Gane E, Leung N, et al. 2-year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009;136:486-495
12. Di Bisceglie AM, Lai CL, Gane E, et al. Telbivudine GLOBE trial: maximal early HBV suppression is predictive of optimal two-year efficacy in nucleoside-treated hepatitis B patients. Hepatology 2006;44(suppl):A230-1.
13. Tenny DJ, Pokornowsky KA, Rose RE, et al. Entecavir at five years shows long-term maintenance of high genetic barrier to hepatitis B virus resistance [abstract]. Hepatol Int 2008;2:A88-9.
14. Marcellin P, Buti M, Krastev Z, et al. A randomized, double-blind, comparison of tenofovir DF (TDF) versus adefovir dipivoxil (ADV) for the treatment of HBeAg-negative chronic hepatitis B (CHB): study GS-US-174-10102 [abstract]. Hepatology 2007;46:80A.
15. Heathcote EJ, Gane E, DeMan R, et al. A randomized, double-blind, comparision of tenofovir DF (TDF) versus adefovir dipivoxil (ADV) for the treatment of HBeAg-positive chronic hepatitis B (CHB): study GS-US-174-10103 [abstract]. Hepatology 2007;46:861A.
16. Nguyen MH, Keeffe EB. Chronic hepatitis B: early viral suppression and long-term outcomes of therapy with oral nucleos(t)ides. J Viral Hepat 2009;16:149-155
17. van Bömmel F, Wunsche T, Mauss S, et al. Comparison of adefovir and tenofovir in the treatment of lamivudine resistant hepatitis B virus infection. Hepatology 2004;40:1421-1425 (Pubitemid 39657017)
18. Peters MG, Andersen J, Lynch P, et al. Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127. Hepatology 2006;44:1110-1116 (Pubitemid 44748362)
19. Lacombe K, Gozlan J, Boyd A, et al. Comparison of the antiviral activity of adefovir and tenofovir on hepatitis B virus in HIV-HBV coinfected patients. Antivir Ther 2008;13:705-713
20. Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008;359:2442-2455
21. Yatsuji H, Suzuki F, Sezaki H, et al. Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: two-year follow-up. J Hepatol 2008;48:923-931
22. Grim SA, Romanelli F. Tenofovir disoproxil fumarate. Ann Pharmacother 2003;37:849-859
23. Stephan C, Berger A, Carlebach A, et al. Impact of tenofovir-containing antiretroviral therapy on chronic hepatitis B in a cohort co-infected with human immunodeficiency virus. J Antimicrob Chemother 2005;56:1087-1093 (Pubitemid 43009825)
24. Lacombe K, Gozlan J, Boelle PY, et al. Long-term hepatitis B virus dynamics in HIV-hepatitis B virus co-infected patients treated with tenofovir disoproxil fumarate. AIDS 2005;19:907-915 (Pubitemid 40834933)
25. Sheldon J, Camino N, Rodes B, et al. Selection of hepatitis B virus polymerase mutations in HIV co-infected patients treated with tenofovir. Antivir Ther 2005;10:727-734 (Pubitemid 41376852)
26. Brunelle MN, Jacquard AC, Pichoud C, et al. Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. Hepatology 2005;41:1391-1398 (Pubitemid 40770292)
27. Qi X, Xiong S, Yang H, Miller M, Delaney WE. In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents. Antivir Ther 2007;12:355-362
28. Kearney BP, Flaherty JF, Sayre JR, et al. Effect of formulation and food on the pharmacokinetics of tenofovir DF. Presented at the second international workshop on clinical pharmacology of HIV therapy, Noordwijk, the Netherlands, April 2-4, 2001.
29. Delaney WE, Ray AS, Yang H, et al. Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus. Antimicrob Agents Chemother 2006;50:2471-2477 (Pubitemid 43993188)
30. Pham PA, Gallant JE. Tenofovir disoproxil fumarate for the treatment of HIV infection. Expert Opin Drug Metab Toxicol 2006;2:459-469 (Pubitemid 46141409)
31. Nunez M, Perez-Olmeda M, Diaz B, Rios P, Gonzalez-Lahoz J, Soriano V. Activity of tenofovir on hepatitis B virus replication in HIV-co-infected patients failing or partially responding to lamivudine. AIDS 2002;16:2352-2354 (Pubitemid 35449029)
32. Ristig MB, Crippin J, Aberg JA, et al. Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus-hepatitis B virus coinfected individuals for whom interferon-alpha and lamivudine therapy have failed. J Infect Dis 2002;186:1844-1847 (Pubitemid 35463519)
33. Nelson M, Portsmouth S, Stebbing J, et al. An open-label study of tenofovir in HIV-1 and hepatitis B virus co-infected individuals. AIDS 2003;17:F7-10. (Pubitemid 36106292)
34. Benhamou Y, Tubiana R, Thibault V. Tenofovir disoproxil fumarate in patients with HIV and lamivudine-resistant hepatitis B virus. N Engl J Med 2003;348:177-178 (Pubitemid 36056731)
35. Dore GJ, Cooper DA, Pozniak AL, et al. Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naïve and - experienced patients coinfected with HIV-1 and hepatitis B virus. J Infect Dis 2004;189:1185-1192 (Pubitemid 38457242)
36. Benhamou Y, Fleury H, Trimoulet P, et al. Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients. Hepatology 2006;43:548-555
37. Jain MK, Comanor L, White C, et al. Treatment of hepatitis B with lamivudine and tenofovir in HIV-HBV-coinfected patients: factors associated with response. J Viral Hepat 2007;14:176-182 (Pubitemid 46257186)
38. Matthews GV, Avihingsanon A, Lewin SR, et al. A randomized trial of combination hepatitis B therapy in HIV-HBV-coinfected antiretroviral na.ve individuals in Thailand. Hepatology 2008;48:1062-1069
39. Schmutz G, Nelson M, Lutz T, et al. Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection. AIDS 2006;20:1951-1954 (Pubitemid 44427612)
40. Matthews GV, Seaburg E, Dore GJ, et al. Combination HBV therapy is linked to greater HBV DNA suppression in a cohort of lamivudine-experienced HIV/HBV coinfected individuals [published online ahead of print July 3, 2009]. AIDS 2009. Available from http://journals.lww.com/aidsonline/Abstract/publishahead/ combination-HBV-therapy-is-linked-to-greater-HBV.99787.aspx. Accessed July 23, 2009.
41. Soriano V, Puoti M, Bonacini M, et al. Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV international panel. AIDS 2005;19:221-240 (Pubitemid 40396554)
42. Matthews GV, Cooper DA, Dore GJ. Improvements in parameters of end-stage liver disease in patients with HIV/HBV-related cirrhosis treated with tenofovir. Antivir Ther 2007;12:119-122
43. Gutiérrez S, Guillemi S, Jahnke N, Montessori V, Harrigan PR, Montaner JS. Tenofovir-based rescue therapy for advanced liver disease in 6 patients coinfected with HIV and hepatitis B virus and receiving lamivudine. Clin Infect Dis 2008;46:e28-30. (Pubitemid 351263551)
44. Kuo A, Dienstag JL, Chung RT. Tenofovir disoproxil fumarate for the treatment of lamivudine-resistant hepatitis B. Clin Gastroenterol Hepatol 2004;2:266-272 (Pubitemid 38293315)
45. van Bömmel F, Zöllner B, Sarrazin C, et al. Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. Hepatology 2006;44:318-325 (Pubitemid 44214870)
46. Santos SA, Uriel AJ, Park JS, et al. Effect of switching to tenofovir with emtricitabine in patients with chronic hepatitis B failing to respond to an adefovir-containing regimen. Eur J Gastroenterol Hepatol 2006;18:1247-1253
47. Schildgen O, Sirma H, Funk A, et al. Variant of hepatitis B virus with primary resistance to adefovir. N Engl J Med 2006;354:1807-1812 (Pubitemid 44079361)
48. van Bömmel F, de Man RA, Stein K, et al. A multicenter analysis of antiviral response after one year of tenofovir monotherapy in HBV-monoinfected patients with prior nucleos(t)ide analog experience [abstract]. J Hepatol 2008;48:A73.
49. Choe WH, Kwon SY, Kim BK, et al. Tenofovir plus lamivudine as rescue therapy for adefovir-resistant chronic hepatitis B in hepatitis B e antigen-positive patients with liver cirrhosis. Liver Int 2008;28:814-820
50. Neff GW, Nery J, Lau DT, et al. Tenofovir therapy for lamivudine resistance following liver transplantation. Ann Pharmacother 2004;38:1999-2004. (Pubitemid 40169365)
51. Schildgen O, Hartmann H, Gerlich WH. Replacement of tenofovir with adefovir may result in reactivation of hepatitis B virus replication. Scand J Gastroenterol 2006;41:245-246 (Pubitemid 43247209)
52. van Bömmel F, Berg T. Reactivation of viral replication after replacement of tenofovir by adefovir. Hepatology 2005;42:239-240 (Pubitemid 40911336)
53. Leemans WF, Janssen HL, Niesters HG, de Man RA. Switching patients with lamivudine resistant chronic hepatitis B virus from tenofovir to adefovir results in less potent HBV-DNA suppression. J Viral Hepat 2008;15:108-114
54. Del Poggio P, Zaccanelli M, Oggionni M, Colombo S, Jamoletti C, Puhalo V. Low-dose tenofovir is more potent than adefovir and is effective in controlling HBV viremia in chronic HbeAg-negative hepatitis B. World J Gastroenterol 2007;13:4096-4099 (Pubitemid 47323163)
55. Tan J, Degertekin B, Wong SN, Husain M, Oberhelman K, Lok AS. Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations. J Hepatol 2008;48:391-398
56. Berg T, Moller B, Trinh H, et al. Tenofovir disoproxil fumarate (TDF) versus emtricitabine plus TDF for treatment of chronic hepatitis B (CHB) in subjects with persistent viral replication receiving adefovir dipivoxil (ADV) [abstract]. J Hepatol 2008;48:A76.
57. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine when used in combination with lamivudine and efavirenz in antiretroviral-na.ve patients: a 3-year randomized trial. JAMA 2004;292:191-201. (Pubitemid 38917996)
58. Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine and efavirenz vs zidovudine, lamivudine and efavirenz for HIV. N Engl J Med 2006;354:251-260
59. Squires K, Pozniak AL, Pierone G, et al. Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial. Ann Intern Med 2003;139:313-320 (Pubitemid 38124586)
60. Peyriere H, Reynes J, Rouanet I, et al. Renal tubular dysfunction associated with tenofovir therapy: report of 7 cases. J Acquir Immune Defic Syndr 2004;35:269-273 (Pubitemid 38280652)
61. Blick G, Grieger-Zanlungo P, Garton T, Hatton E, Lopez RJ. Tenofovir may cause severe hypophosphatemia in HIV/AIDS patients with prior adefovir-induced renal tubular acidosis. Presented at the 10th conference on retroviruses and opportunistic infections, Boston, MA, February 10-14, 2003.
62. Karras A, Lafaurie M, Furco A, et al. Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus. Clin Infect Dis 2003;36:1070-1073 (Pubitemid 36513295)
63. Rifkin BS, Perazella MA. Tenofovir-associated nephrotoxicity: Fanconi syndrome and renal failure. Am J Med 2004;117:282-284 (Pubitemid 39092726)
64. Hansen AB, Mathiesen S, Gerstoft J. Severe metabolic acidosis and renal failure in an HIV-1 patient receiving tenofovir. Scand J Infect Dis 2004;36:389-392 (Pubitemid 38967701)
65. Barrios A, Garcia-Benayas T, Gonzáles-Lahoz J, et al. Tenofovir-related nephrotoxicity in HIV-infected patients. AIDS 2004;18:960-963
66. James CW, Steinhaus MC, Szabo S, Dressier RM. Tenofovir-related nephrotoxicity: case report and review of the literature. Pharmacotherapy 2004;24:415-418 (Pubitemid 38298769)
67. Zimmermann A, Pizzoferrato T, Bedford J, et al. Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions. Clin Infect Dis 2006;42:283-290 (Pubitemid 43054205)
68. Gallant J, Parish M, Keruly J, Moore R. Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse transcriptase inhibitor treatment. Clin Infect Dis 2005;40:1194-1198 (Pubitemid 40490248)
69. Gallant JE, Parish MA, Keruly JC, et al. Tenofovir and changes in renal function [letter reply]. Clin Infect Dis 2005;41:571.
70. Antoniou T, Raboud J, Chirhin S, et al. Incidence of and risk factors for tenofovir-induced nephrotoxicity: a retrospective cohort study. HIV Med 2005;6:284-290 (Pubitemid 41025294)